PhageTech aims to revolutionize and simplify disease diagnosis by providing actionable, molecular insight to physicians within minutes at the point-of-care.The company was cofounded by Richard Henson, and UCI chemistry professors Gregory Weiss and Reginald Penner. PhageTech’s patented BioSensor™ technology was developed during 10 years of NIH and NSF-funded research at UCI. The company’s electrochemical biosensor platform can perform simple, low cost diagnostic testing directly from body fluids such as urine and blood without complex sample preparation or reagents, and can be used by minimally-trained medical staff.
Glaucoma is a general grouping of eye diseases that impact the optic nerve, resulting in progressive vision loss. According to the NIH National Eye Institute, currently, over 2.7 million Americans suffer from glaucoma, and approximately 11 million are projected to be afflicted by 2050. For many years, clinicians have struggled to find an efficacious treatment for glaucoma. To date, first-line drugs have had limited effectiveness due to progression of the disease or low patient compliance, and conventional surgical methods lacked the efficacy to produce a long-term cure. In the late 1990s, researchers began thinking about non-traditional approaches for
Professor and inventor Michael Demetriou has been studying immune-related diseases and cancers long before founding GlyTR Therapeutics in 2015. Prof. Demetriou’s research focuses on aberrant protein glycosylation that occurs in diseased cells. Glycosylation, the addition of sugars or glycans to proteins and other biomolecules, is an important method cells use to define the structure, function, and transportation of the molecule.